Conditioned Generative Modeling of Molecular Glues: A Realistic AI Approach for Synthesizable Drug-Like Molecules
Preprint
- 29 April 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Alzheimer’s disease (AD) is marked by the pathological accumulation of amyloid beta-42 (Aβ42), contributing to synaptic dysfunction and neurodegeneration. While extracellular amyloid plaques are well-studied, increasing evidence highlights intracellular Aβ42 as an early and toxic driver of disease progression. In this study, we present a novel, AI-assisted drug design approach to promote targeted degradation of Aβ42 via the ubiquitin-proteasome system (UPS), using E3 ligase–directed molecular glues. We systematically evaluated the ternary complex formation potential of Aβ42 with three E3 ligases—CRBN, VHL, and MDM2—through structure-based modeling, ADMET screening, and docking. We then developed a Ligase-Conditioned Junction Tree Variational Autoencoder (LC-JT-VAE) to generate ligase-specific small molecules, incorporating protein sequence embeddings and torsional angle-aware molecular graphs. Our results demonstrate that this generative model can produce chemically valid, novel, and target-specific molecular glues capable of facilitating Aβ42 degradation. This integrated approach offers a promising framework for designing UPS-targeted therapies for neurodegenerative diseases.Keywords
All Related Versions
- Version 1, 2025-04-29, Preprints
- Published version: Biomolecules, 15 (6), 849.
This publication has 49 references indexed in Scilit:
- RGCVAE: relational graph conditioned variational autoencoder for molecule designMachine Learning, 2025
- Advances in Artificial Intelligence (AI)-assisted approaches in drug screeningArtificial Intelligence Chemistry, 2023
- Chemoproteomics-enabled discovery of a covalent molecular glue degrader targeting NF-κBCell Chemical Biology, 2023
- Deep generative models for ligand‐based de novo design applied to multi‐parametric optimizationJournal of Computational Chemistry, 2022
- Artificial intelligence in drug discovery and developmentDrug Discovery Today, 2021
- Targeted protein degradation: current and future challengesCurrent Opinion in Chemical Biology, 2020
- From Discovery to Bedside: Targeting the Ubiquitin SystemCell Chemical Biology, 2019
- Investigating Protein–Peptide Interactions Using the Schrödinger Computational Suite2017
- Identification of novel natural compound inhibitors for human complement component 5a receptor by homology modeling and virtual screeningMedicinal Chemistry Research, 2016
- Intraneuronal accumulation of Aβ42 induces age-dependent slowing of neuronal transmission in DrosophilaNeuroscience Bulletin, 2014